10x Genomics price to book ratio TXG

Market value divided by the book value of the company's net assets, since 2019.

Today, Oct 23, 2026: 11.3×
7-year median: 7.2×
Against its 7-year history: 66th; percentile: 0 is its lowest day, 100 its highest
7-year range: 1.3× to 42.0×
Peer median: 4.3×

10x Genomics' price to book ratio is 11.3× as of Oct 23, 2026.

That is above its 7-year median of 7.2×, higher than on 66% of days in the last 7 years.

Over that time it ranged from 1.3× in Apr 2025 to 42.0× in Oct 2020.

The median for 10 diagnostics and research stocks of a similar size is 4.3×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	11.3×	2.7×	14.8×
2025	2.7×	1.3×	3.0×
2024	2.4×	2.2×	8.2×
2023	8.9×	5.4×	9.1×
2022	5.4×	3.7×	17.8×
2021	20.8×	19.3×	29.1×
2020	18.5×	12.8×	42.0×
2019	17.8×	13.9×	17.8×

Against its peers

Companies in Medical - Diagnostics & Research nearest 10x Genomics' size, closest first, today.

Company	Price to book ratio
TXG10x Genomics	11.3×
CAICaris Life Sciences	15.3×
BIOBio-Rad Laboratories	1.4×
LNTHLantheus	5.0×
BLLNBillionToOne	9.5×
RVTYRevvity	2.5×
MEDPMedpace	43.1×
VCYTVeracyte	2.8×
CDNACareDx	8.4×
LHLabcorp	3.1×
DGXQuest Diagnostics	3.6×
Peer median	4.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on 10x Genomics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.